Kura Oncology (NASDAQ:KURA) Insider Sells $173,122.30 in Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Mollie Leoni sold 15,485 shares of the company’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $11.18, for a total value of $173,122.30. Following the transaction, the insider owned 225,454 shares of the company’s stock, valued at approximately $2,520,575.72. The trade was a 6.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Mollie Leoni also recently made the following trade(s):

• On Monday, September 29th, Mollie Leoni sold 12,314 shares of Kura Oncology stock. The shares were sold at an average price of $8.94, for a total value of $110,087.16.

Kura Oncology Trading Up 4.9%

Shares of Kura Oncology stock traded up $0.52 during trading on Friday, hitting $11.20. 4,478,689 shares of the stock were exchanged, compared to its average volume of 2,241,571. Kura Oncology, Inc. has a 12 month low of $5.41 and a 12 month high of $16.68. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 0.02. The stock’s fifty day moving average is $9.46 and its 200 day moving average is $7.48.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). Kura Oncology had a negative net margin of 208.48% and a negative return on equity of 65.42%. The business had revenue of $20.75 million for the quarter, compared to the consensus estimate of $17.48 million. On average, research analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on KURA shares. UBS Group raised their price target on Kura Oncology from $14.00 to $16.00 and gave the company a “buy” rating in a report on Friday. Wedbush restated an “outperform” rating and set a $38.00 price target (up from $36.00) on shares of Kura Oncology in a research report on Friday. Wall Street Zen raised shares of Kura Oncology from a “sell” rating to a “hold” rating in a research note on Sunday, August 17th. JMP Securities reiterated a “market outperform” rating and set a $24.00 price objective on shares of Kura Oncology in a research note on Monday, October 20th. Finally, Guggenheim initiated coverage on Kura Oncology in a research report on Thursday, September 4th. They issued a “neutral” rating for the company. Ten equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $25.11.

Institutional Trading of Kura Oncology

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC boosted its holdings in Kura Oncology by 392.8% during the third quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock worth $34,000 after buying an additional 3,072 shares in the last quarter. State of Wyoming acquired a new stake in shares of Kura Oncology during the 1st quarter valued at $48,000. PNC Financial Services Group Inc. boosted its stake in shares of Kura Oncology by 127.2% during the 3rd quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock worth $60,000 after acquiring an additional 3,769 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Kura Oncology by 471.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock worth $70,000 after acquiring an additional 9,958 shares during the last quarter. Finally, Pallas Capital Advisors LLC grew its holdings in shares of Kura Oncology by 32.2% in the 2nd quarter. Pallas Capital Advisors LLC now owns 13,304 shares of the company’s stock worth $77,000 after acquiring an additional 3,241 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.